Alli Pioneers EU Centralized Process For Nonprescription Switch
This article was originally published in The Tan Sheet
Executive Summary
The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process
You may also be interested in...
EU Centralized Switch Process Needs Longer Exclusivity, More Trust - Execs
Limited data protection and a lack of trust between industry and regulators are dampening enthusiasm for the European Union's centralized switch process, according to industry leaders
Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries
Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed
European Switch Progresses, But Stronger Incentives Needed For OTCs
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20